



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Heeney, et al.  
SERIAL NO: 10/502,031  
FILED: July 20, 2004  
EXAMINER: Unassigned ART UNIT: Unassigned  
FOR: Treatment of MS with Goat Serum  
ATTY DKT NO.: 430500.11  
CUSTOMER No.: 27162

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449, which may be material to the patentability of the above-identified application. Applicant(s) make no admission that the cited references are prior art or that these references are in fact material to the patentability of the above-entitled application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits. No fee or statement is required; OR
- (4) Before the mailing of a first Office Action after the filing of a request for continued examination under §1.114

\_\_\_\_§1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

- \_\_\_\_ The statement as specified in 37 CFR §1.97(e) set out below; OR
- \_\_\_\_ The fee of \$180.00 under 37 CFR §1.17(p).

\_\_\_\_§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND  
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$180.00 set out in 37 CFR §1.17(i).

\_\_\_\_§1.97(e) The undersigned Attorney hereby states that:

- \_\_\_\_ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;
- or
- \_\_\_\_ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Examiner is respectfully requested to consider and make of record all of the cited documents.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

**FIRST CLASS CERTIFICATE**

I hereby certify that this correspondence is being deposited on the date set forth below with the U.S. Postal Service as First Class Mail, postage prepaid, in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Raymond J. Lillie 9/25/09  
Raymond J. Lillie Date

Respectfully submitted,

Raymond J. Lillie

Raymond J. Lillie, Reg. No. 31,778  
Attorney for Applicants

CARELLA, BYRNE, BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN

5 Becker Farm Road  
Roseland, NJ 07068

Tel: (973)994-1700

Fax: (973)994-1744